Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse drug reaction characterized by progressive bone destruction and necrosis of mandibular and/or maxillary jaw bone that occurs in patients undergoing treatments with antiresorptive drugs such as bisphosphonates or...
treating hypercalcaemia and chemotherapy-induced bone loss (Coleman in Clin Cancer Res 12: 6243s–6249s, 2006), (Coleman in Ann Oncol 31: 1650–1663, 2020). Two decades ago, medication-related osteonecrosis of the jaw (MRONJ
The following search terms were used: “osteonecrosis of the jaw,”“jaw necrosis,”“antiresorptive agent,”“bisphosphonate(s),”“denosumab,”“medication,”“antiresorptive(s),”“antiresorptive agent,”“denture,”“prosthesis,”“obturator,”“rehabilitation,”“prosthodontic treatment,”“clinical...
Medication-related osteonecrosis of the jaw associated with aflibercept. The British journal of oral & maxillofacial surgery. 2017;55(3):314-5.Zarringhalam P, Brizman E, Shakib K. Medication-related os- teonecrosis of the jaw associated with aflibercept. Br J Oral Maxillofac Surg. 2017;55:...
In the treatment of bone metastases from breast cancer, bisphosphonates are considered the cornerstone of treatment to prevent adverse skeletal related events. Intravenous bisphosphonates reduce bone resorption by inhibiting osteoclast function. However, osteonecrosis of the jaws is a commonly reported side ...
Medication-related osteonecrosis of the jaw (MRONJ), although initially believed to be exclusively associated with bisphosphonates, has been implicated in recent reports with additional drugs, especially the bone antiresorptive denosumab. The pathophysiology has not been fully elucidated, and no causal as...
Medication-Related Osteonecrosis of the Jaw (MRONJ) is a challenging affection, considering the absence of a Gold Standard treatment. Cell therapy and tissue engineering, using Adipose-Tissue Stromal Vascular Fraction (SVF) containing Mesenchymal Stromal Cells (MSC) and Endothelial Progenitor Cells (EPC...
Medication-related osteonecrosis of the jaw (MRONJ) primarily involves patients receiving intravenous bisphosphonates for treatment of skeletal-related malignancies, oral bisphosphonates, and denosumab. There is no consensus regarding the clinical management of MRONJ. Successful treatment may be that which ...
Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal-related events [SREs] in patients with cancer and bone metastases) or possibly anti-angiogenic cancer treatment. While the...
osteonecrosisRetrospectiveanalysisObjectives This study reviews the treatment outcome of patients (1) who referred to our hospital for preventive care using both bisphosphonate and related drugs (Non-MRONJ patient) and (2) who already have ongoing MRONJ symptoms (MRONJ patient) based on the AAOMS'...